The board’s decision follows a previously announced dual-track strategic review that considered a sale or spin-off of the medtech business alongside continued operation.

Rather than either of those paths, the board has resolved to wind the medtech operations down in an orderly fashion, while the company concentrates its resources on its Nordic property portfolio going forward. It marks the completion of a shift that began with Episurf’s earlier move to build a new property-focused business segment alongside its original orthopaedic implant technology.